Many firms view patient engagement as a compliance task that adds cost. However, data shows integrating patient experience into development from the start speeds up clinical trial recruitment and execution, reduces FDA amendments, and accelerates time-to-market, providing clear ROI.

A common failure in biotech is viewing patients solely as data sources rather than as human partners in the development process. This perspective leads to unnecessarily complex protocols with high patient burden. The most successful firms build relationships with patient advocacy groups and design trials that respect the patient's experience.

Instead of a total overhaul, we can accelerate trials with three changes: 1) A simple patient opt-in registry for trial participation. 2) Collaborative platform trials testing multiple drugs against one control group. 3) A shared database for all trial data, including failures.

The economic case for a prophylactic drug isn't just clinical. Its real value is enabling expensive, multi-week inpatient procedures (like CAR-T side effect observation) to become outpatient treatments, freeing up hospital beds and massively reducing healthcare system costs.

Beyond medical side effects, clinical trials impose a significant 'procedural burden' on patients: frequent travel, extra blood draws, and endless questionnaires. This human cost must be minimized, as it can disrupt a patient's life and limit participation for those without strong support systems.

Many clinical trials fail not because the science is wrong, but because of operational issues like patient recruitment and retention. These problems often stem from overly burdensome and rigid trial designs that deter participation, a preventable error.

Industry leaders often believe their clinical trial designs are patient-centric, but direct experience in community clinics reveals the significant burden placed on patients and caregivers, such as 12-hour blood draw days. This exposure leads to more practical and humane trial designs that improve real-world data collection.

The median $40,000 cost per trial enrollee is high because pharma companies essentially run a parallel, premium healthcare system for participants. They pay for all care and level it up globally to standardize the experiment.

True scaling of complex treatments goes beyond logistics. It requires building flexibility into the system to accommodate patients' variable health, reducing the emotional and financial burden of travel for them and their families.